首页> 美国卫生研究院文献>Journal of Lipid Research >Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure
【2h】

Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure

机译:心力衰竭发展过程中心磷脂的生物合成和重塑酶发生改变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiolipin (CL) is responsible for modulation of activities of various enzymes involved in oxidative phosphorylation. Although energy production decreases in heart failure (HF), regulation of cardiolipin during HF development is unknown. Enzymes involved in cardiac cardiolipin synthesis and remodeling were studied in spontaneously hypertensive HF (SHHF) rats, explanted hearts from human HF patients, and nonfailing Sprague Dawley (SD) rats. The biosynthetic enzymes cytidinediphosphatediacylglycerol synthetase (CDS), phosphatidylglycerolphosphate synthase (PGPS) and cardiolipin synthase (CLS) were investigated. Mitochondrial CDS activity and CDS-1 mRNA increased in HF whereas CDS-2 mRNA in SHHF and humans, not in SD rats, decreased. PGPS activity, but not mRNA, increased in SHHF. CLS activity and mRNA decreased in SHHF, but mRNA was not significantly altered in humans. Cardiolipin remodeling enzymes, monolysocardiolipin acyltransferase (MLCL AT) and tafazzin, showed variable changes during HF. MLCL AT activity increased in SHHF. Tafazzin mRNA decreased in SHHF and human HF, but not in SD rats. The gene expression of acyl-CoA: lysocardiolipin acyltransferase-1, an endoplasmic reticulum MLCL AT, remained unaltered in SHHF rats. The results provide mechanisms whereby both cardiolipin biosynthesis and remodeling are altered during HF. Increases in CDS-1, PGPS, and MLCL AT suggest compensatory mechanisms during the development of HF. Human and SD data imply that similar trends may occur in human HF, but not during nonpathological aging, consistent with previous cardiolipin studies.
机译:心磷脂(CL)负责调节参与氧化磷酸化的各种酶的活性。尽管心力衰竭(HF)的能量产生减少,但在HF发生期间对心磷脂的调节尚不清楚。在自发性高血压HF(SHHF)大鼠,人类HF患者的离体心脏和无衰竭Sprague Dawley(SD)大鼠中研究了参与心脏心磷脂合成和重塑的酶。研究了生物合成酶胞苷二磷酸二甘油甘油合成酶(CDS),磷脂酰甘油磷酸合成酶(PGPS)和心磷脂合成酶(CLS)。 HF线粒体CDS活性和CDS-1 mRNA升高,而SHHF和人类(而非SD大鼠)的CDS-2 mRNA降低。在SHHF中,PGPS活性增加了,但mRNA没有增加。 SHHF中的CLS活性和mRNA下降,但在人类中,mRNA没有明显改变。心磷脂重塑酶,单溶心磷脂酰基转移酶(MLCL AT)和他法嗪在HF期间显示出可变的变化。 SHHF中MLCL AT活性增加。在SHHF和人HF中,Tafazzin mRNA降低,但SD大鼠未降低。内源性内质网MLCL AT的酰基辅酶A基因:溶血心磷脂酰基转移酶-1的基因表达在SHHF大鼠中保持不变。该结果提供了在HF期间心磷脂生物合成和重塑均改变的机制。 CDS-1,PGPS和MLCL AT的增加提示HF发生过程中的补偿机制。人类和SD数据暗示人类HF可能出现类似趋势,但在非病理性衰老过程中不会发生,这与先前的心磷脂研究一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号